Literature DB >> 22189977

The impact of human gene polymorphisms on HCV infection and disease outcome.

Esperance A K Schaefer1, Raymond T Chung.   

Abstract

In recent years, some genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with hepatitis C viral containment, treatment response, and disease progression. IL28B is a gene on chromosome 19, coding for interferon-λ3, and two polymorphisms upstream of this the gene have been strongly associated with clinical outcomes after treatment for the hepatitis C virus (HCV). The IL28B polymorphisms have additionally been associated with spontaneous clearance. The mechanism has yet to be clearly defined, but appears to involve differential responsiveness to interferon signaling between the favorable and unfavorable genotypes. ITPA is a gene on chromosome 20, coding for inosine triphosphatase, and polymorphisms on this gene have been associated with ribavirin-induced hemolytic anemia. Functional variants of ITPA have been identified that have decreased enzymatic activity, which appear to protect against anemia. Finally, PNPLA3 polymorphisms were initially described as predictors of nonalcoholic fatty liver disease, but have recently been associated with disease progression in HCV. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189977     DOI: 10.1055/s-0031-1297926

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  6 in total

Review 1.  Alcoholic liver disease and hepatitis C virus infection.

Authors:  Ignacio Novo-Veleiro; Lucía Alvela-Suárez; Antonio-Javier Chamorro; Rogelio González-Sarmiento; Francisco-Javier Laso; Miguel Marcos
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

2.  Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.

Authors:  Maryam Ehteshami; Sijia Tao; Tugba Ozturk; Longhu Zhou; Jong Hyun Cho; Hongwang Zhang; Sheida Amiralaei; Jadd R Shelton; Xiao Lu; Ahmed Khalil; Robert A Domaoal; Richard A Stanton; Justin E Suesserman; Biing Lin; Sam S Lee; Franck Amblard; Tony Whitaker; Steven J Coats; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 3.  The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.

Authors:  Ralf Bartenschlager; Volker Lohmann; Francois Penin
Journal:  Nat Rev Microbiol       Date:  2013-06-10       Impact factor: 60.633

4.  Association between Hepatitis C Virus Viremia and the rs12979860, rs2228145 and rs1800795 SNP (CT/AC/GG) Genotype in Saudi Kidney Transplant Recipients.

Authors:  Khaled R Alkharsah; Alhussain J Alzahrani; Obeid E Obeid; Reem Y Aljindan; Adnane Guella; Amein K Al-Ali; Hussain R Al-Turaifi; Talal A Sallam
Journal:  Saudi J Med Med Sci       Date:  2019-12-23

5.  Expansion of a 12-kb VNTR containing the REXO1L1 gene cluster underlies the microscopically visible euchromatic variant of 8q21.2.

Authors:  Christine Tyson; Andrew J Sharp; Monica Hrynchak; Siu L Yong; Edward J Hollox; Peter Warburton; John Ck Barber
Journal:  Eur J Hum Genet       Date:  2013-09-18       Impact factor: 4.246

6.  Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.

Authors:  Fatimah S Alhamlan; Mohammed N Al-Ahdal; Nisreen Z Khalaf; Ayman A Abdo; Faisal M Sanai; Hamad I Al-Ashgar; Mahmoud ElHefnawi; Amina Zaid; Ahmed A Al-Qahtani
Journal:  J Transl Med       Date:  2014-04-06       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.